- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04158466
A Study to Evaluate the Safety and Efficacy of Kalifilcon A Daily Disposable Contact Lens
October 26, 2020 updated by: Bausch & Lomb Incorporated
A Study to Evaluate the Safety and Efficacy of a Kalifilcon A Contact Lens for Daily Disposable Use
This study is to evaluate the safety and efficacy of a new silicone hydrogel daily disposable contact lens, kalifilcon A compared to the Bausch + Lomb Biotrue ONE day® daily disposable contact lens when worn by current soft contact lens wearers on a daily disposable wear basis.
Study Overview
Status
Completed
Conditions
Detailed Description
Approximately 247 participants (494 eyes) will be enrolled in at approximately 20 investigative sites in the United States (US).
A minimum of 20% of the randomized participants will be of Japanese descent (for example, both maternal and paternal grandparents born in Japan).
Study Type
Interventional
Enrollment (Actual)
252
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90012
- Bausch Site 8
-
San Francisco, California, United States, 94112
- Bausch Site 9
-
Torrance, California, United States, 90503
- Bausch Site 10
-
Torrance, California, United States, 90505
- Bausch Site 12
-
-
Florida
-
Sarasota, Florida, United States, 34237
- Bausch Site 6
-
-
Hawaii
-
'Aiea, Hawaii, United States, 96701
- Bausch Site 4
-
Honolulu, Hawaii, United States, 96814
- Bausch Site 16
-
-
Kansas
-
Pittsburg, Kansas, United States, 66762
- Bausch Site 7
-
-
Minnesota
-
Bloomington, Minnesota, United States, 61701
- Bausch Site 11
-
-
Missouri
-
Saint Louis, Missouri, United States, 63144
- Bausch Site 1
-
-
New York
-
Vestal, New York, United States, 13850
- Bausch Site 13
-
-
Pennsylvania
-
State College, Pennsylvania, United States, 16801
- Bausch Site 2
-
-
Tennessee
-
Brentwood, Tennessee, United States, 37027
- Bausch Site 14
-
Memphis, Tennessee, United States, 38119
- Bausch Site 5
-
Nashville, Tennessee, United States, 37205
- Bausch Site 3
-
-
Wisconsin
-
New Berlin, Wisconsin, United States, 53151
- Bausch Site 15
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants must be able to read, understand, and provide written informed consent on the Institutional Review Board (IRB) approved Informed Consent Form (ICF) and provide authorization as appropriate for local privacy regulations.
- Participants must be myopic and require lens correction from -0.25 to -6.00 Diopter (D) with 0.25 D steps, in each eye.
- Participants must be correctable through spherocylindrical refraction and with soft spherical contact lenses to 40 letters (0.14 logMAR) or better (2 meters distance, high-contrast chart) in each eye.
- Participants must be free of any anterior segment disorders.
- Participants must be adapted soft contact lens wearers and willing to wear their study lenses for at least 8 hours per day at least 5 days per week on a daily disposable wear basis for approximately 3 months.
- Participants must be willing and able to comply with all treatment and follow-up/study procedures, as well as willing and able to refrain from using any other contact lenses or solutions other than those provided for the duration of the study.
Exclusion Criteria:
- Participation in any drug or device clinical investigation within 2 weeks prior to entry into this study (Screening/Dispensing Visit) and/or during the period of study participation.
- Participants who are women of childbearing potential (those who are not surgically sterilized or postmenopausal) are excluded from participation in the investigation if they are currently pregnant, plans to become pregnant during the study, or is breastfeeding
- Participants who have worn gas permeable (GP) contact lenses within the last 30 days or who have worn polymethylmethacrylate (PMMA) lenses within the last 3 months.
- Participants with any systemic disease currently affecting ocular health or in the Investigator's opinion may have an effect on ocular health during the course of the study.
- Participants using any systemic or topical medications that will, in the Investigator's opinion, affect ocular physiology or lens performance.
- Participants with an active ocular disease or who are using any ocular medication.
- Participants who currently wear monovision, multifocal, or toric contact lenses.
- Participants with an ocular astigmatism of greater than 1.00 D in either eye.
- Participants with anisometropia (spherical equivalent) of greater than 2.00 D.
- Participants with any Grade 2 or greater finding during the slit lamp examination. Participants with corneal infiltrates of any grade.
- Participants with any "Present" finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear.
- Participants with any scar or neovascularization within the central 6 millimeters (mm) of the cornea.
- Participants who are aphakic.
- Participants who are amblyopic.
- Participants who have had any corneal surgery (for example, refractive surgery).
- Participants who are allergic to any component in the study care products.
- The participant is an employee of the investigative site.
- The participant, or a member of the participant's household, is an Ophthalmologist, an Optometrist, an Optician, or an Ophthalmic Assistant/Technician.
- The participant, or a member of the participant's household, is an employee of a manufacturer of contact lenses or contact lens care products (for example, Alcon, Bausch + Lomb, Ciba Vision, CooperVision, Johnson & Johnson).
- The participant, or a member of the participant's household, is an employee of a market research firm.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Kalifilcon A Daily Disposable Contact Lenses
Participants will wear Bausch + Lomb kalifilcon A daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months.
Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
|
Contact lens
|
Active Comparator: Biotrue ONEday Daily Disposable Contact Lenses
Participants will wear Bausch + Lomb Biotrue ONEday daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months.
Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
|
Contact lens
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean logMAR Contact Lens Visual Acuity
Time Frame: 3 months
|
Visual acuity (VA) will be reported as letters read correctly, and the letters read will be converted to logarithm of the minimum angle of resolution (logMAR) acuity.
The participant will read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters.
The total number of correct letters will be recorded.
A decrease in the number of correct letters indicates a decrease in visual acuity.
Acuity will be averaged across visits.
|
3 months
|
Proportion of Participants With Slit Lamp Findings Greater Than Grade 2
Time Frame: 3 months
|
During an examination of both eyes without lenses, graded slit lamp findings will be assessed for each eye using Grades 0 (none), 1 (trace), 2 (mild), 3 (moderate), and 4 (severe).
Using only the non-missing observations from all visits without imputation, each eye will be classified with respect to findings greater than Grade 2 at any visit (Absent or Present).
Epithelial edema, epithelial microcysts, corneal staining, limbal Injection, bulbar injection, upper lid tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates will be evaluated.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 31, 2019
Primary Completion (Actual)
November 12, 2019
Study Completion (Actual)
November 12, 2019
Study Registration Dates
First Submitted
November 7, 2019
First Submitted That Met QC Criteria
November 7, 2019
First Posted (Actual)
November 8, 2019
Study Record Updates
Last Update Posted (Actual)
November 19, 2020
Last Update Submitted That Met QC Criteria
October 26, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- 890
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contact Lens Wear
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Alcon ResearchCompletedContact Lens WearUnited States
-
Bausch & Lomb IncorporatedCompletedContact Lens WearUnited States
-
Bausch & Lomb IncorporatedCompletedContact Lens WearUnited States
-
Bausch & Lomb IncorporatedCompletedContact Lens WearUnited States
-
Asepticys LLCCompletedContact Lens WearUnited States
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
Clinical Trials on Kalifilcon A Daily Disposable Contact Lenses
-
Bausch & Lomb IncorporatedCompletedAstigmatism | MyopiaUnited States
-
Bausch & Lomb IncorporatedCompleted
-
Bausch & Lomb IncorporatedCompletedMyopia and Hyperopia and PresbyopiaUnited States
-
Ohio State UniversityCompletedContact LensUnited States
-
State University of New York College of OptometryJohnson & Johnson Vision Care, Inc.CompletedAsthenopia | Contact Lenses | Ocular Accommodation | Convergence, ExcessUnited States
-
Bausch & Lomb IncorporatedCompletedMyopiaUnited States
-
Alcon ResearchCompletedMyopia | AmetropiaUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedContact Lens Base Curve (BC) Fit and ComfortUnited States
-
Bausch & Lomb IncorporatedCompleted
-
Johnson & Johnson Vision Care, Inc.CompletedMyopia | HyperopiaUnited States